Equillium Inc reports results for the quarter ended June 30 - Earnings Summary

Equillium

13/08/2026 22:02

Equillium Inc EQ.OQ reported a quarterly adjusted loss of 4 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -16 cents.  The mean expectation of nine analysts for the quarter was for a loss of 5 cents per share. Wall Street expected results to range from -6 cents to -4 cents per share.
Reported revenue was zero​; analysts expected zero. 
Equillium Inc's reported EPS for the quarter was a loss of 4 cents​.
The company reported a quarterly loss of $4.69 million.
Equillium Inc shares had fallen by 31.9% this quarter and gained 40.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 5.9% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Equillium Inc is $7.00, about 68.9% above its last closing price of $2.18
This summary was machine generated from LSEG data August 13 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.05
-0.04
Beat
Mar. 31 2026 
-0.04
-0.06
Missed
Dec. 31 2025 
-0.06
-0.04
Beat
Sep. 30 2025 
-0.14
-0.06
Beat